|
Post by kc on Jun 16, 2018 18:08:41 GMT -5
I hope they have some kind of big splash at ADA for Doctors with registration for having a Rep come into their practice and with Fresh samples. Hopefully Dr. Kendall, the presentations will spark that interest for the Doctors.
|
|
|
Post by kc on Jun 16, 2018 18:04:45 GMT -5
Good thing we have the Pros to counter the Cons Most of the Con Men & Women seem to be in the swamp in DC. Let’s focus on Making Mannkind Great again.
|
|
|
Post by kc on Jun 14, 2018 19:29:44 GMT -5
I once saw a pretty girl name Lilly. I believe she had magic beans too. Lots and lots of magic beans.
|
|
|
Post by kc on Jun 14, 2018 18:37:12 GMT -5
Glad to see that management is putting skin into the game. For such a long time there was anemic holdings by anybody on the management team. Regardless if the shares were gifted or purchased this indication is that positive things are ahead for MannKind.
The seeds have been planted now we just have to wait for them to sprout from the ground.
|
|
|
Post by kc on Jun 11, 2018 6:30:08 GMT -5
|
|
|
Post by kc on Jun 9, 2018 22:39:06 GMT -5
What makes you think they are in that particular booth? (Boehringer Ingelheim Pharmaceuticals, Inc./Eli Lilly stand. ) They are independent companies and normally exhibit separately. They do have the relationship on the biosimilar insulin. to my knowledge they have not exhibited together before? They also offer to many insulin products not to have an exhibit since they are One of the big three companies. www.lillydiabetes.com/lilly-diabetes-medicines.aspxThere is a longstanding partnership between Boehringer and Lilly Diabetes. I believe the partnership is only on one product and that is the Lantus Biosimular product basaglar. I’m not sure the relationship but I believe it’s at Eli Lilly handles the US distribution. Eli Lily is much bigger than just the one product so they would be marketing all of their own products and the joint partnership on one product. www.basaglar.com/en/
|
|
|
Post by kc on Jun 9, 2018 12:10:05 GMT -5
What makes you think they are in that particular booth? (Boehringer Ingelheim Pharmaceuticals, Inc./Eli Lilly stand. ) They are independent companies and normally exhibit separately. They do have the relationship on the biosimilar insulin. to my knowledge they have not exhibited together before? They also offer to many insulin products not to have an exhibit since they are One of the big three companies. www.lillydiabetes.com/lilly-diabetes-medicines.aspx
|
|
|
Post by kc on Jun 8, 2018 23:05:23 GMT -5
|
|
|
Post by kc on Jun 7, 2018 18:47:33 GMT -5
While I was at the corporate website's pipeline page downloading the graphic, I branched out and did a little more exploration of the R&D webpages. This is an interesting little nugget I dug up:
Diverse Compatibility
Our dry powder formulation technology is compatible with a diverse assortment of drugs over a broad range of physicochemical characteristics, including molecular weight (300 – 150,000 Daltons), structure (small molecules to monoclonal antibodies), charge, and hydrophilicity/hydrophobicity. Our dry powders are ideally suited to deliver drugs for local diseases, such asthma and COPD.
In addition, the use of our Technosphere technology for systemic conditions was validated by the FDA approval of AFREZZA® (insulin human) inhalation powder, and has also been demonstrated in clinical studies with Technosphere formulations of parathyroid hormone (PTH/Technosphere), salmon calcitonin (sCT/Technosphere), and glucagon-like peptide 1 (GLP-1/Technosphere).
Source: www.mannkindcorp.com/research-development/tech-platforms/dry-powder-formulation/
---
I wasn't aware that there were clinical studies conducted for these three API.
I few years ago I wrote that if Afrezza is a golden egg, then Technosphere is the goose that laid it. These studies bolster my opinion that, based on Intellectual Property alone, the stock market has greatly undervalued this company.
What is this information (clinical studies) that was possibly found in the treasure trove of studies at Dr. Kendall came across?
|
|
|
Post by kc on Jun 7, 2018 8:29:19 GMT -5
It takes time to turn a ship around. But Mike has done a great job of building a team to move mannkind towards the future.
The best is yet to come.
|
|
|
Post by kc on Jun 5, 2018 9:12:02 GMT -5
I have no issue with it. More skin in the game. Normally purchased shares at a slight discount but not sure on this plan. It might just be at market value. But why not have it? Let them buy shares with Payroll dollars is just like saving in a 401K. Also a GREAT SIGNAL to the street that the company is confident about being around in the future.
|
|
|
Post by kc on Jun 4, 2018 13:50:22 GMT -5
That is because Eli Lilly and Company, Novo Nordisk, and Sanofi each participate in corrupt, collaborative-collusion
MannKind Should make a Paradigm shift and go Cheap and on a direct subscription. Put the big Phama boys to shame.
|
|
|
Post by kc on May 17, 2018 19:46:55 GMT -5
sayhey24... to your #10, it seems bioexec is saying Kindall believes a label change to ultra-rapid can be achieved without additional trials. i wonder if that was already submitted to the fda. Stat and hypo data could likely support that. Perhaps it’s part of the quarantined information that he will present at ADA 2018
|
|
|
Post by kc on May 17, 2018 15:20:01 GMT -5
Also, I was able to try Afrezza for the first time at the welcome dinner thanks to generosity of a fellow investor and inhaled one 4-uint cartridge prior to the start of my 12 oz filet mignon dinner with all the trimmings and w/bread, then the other halfway thru my meal. My BG stayed a rock steady 91. That's incredible. Granted I'm in shape, exercise daily, and have great control, but nothing like that when eating. And using that cool Dreamboat and then actually inhaling Afrezza made me feel like I just walked into the 21st century. I'm the perfect candidate for early intervention of Afrezza that Kendall mentioned as a target market. We'd all thrive on Afrezza for mealtime control, and that's all we'd need. No other drugs necessary. Denise,
That was Al Mann's comment back in 2010. Early Intervention.... Give the pancreas a rest to rejuvenate itself. Maybe Dr. David Kendall can get this research done as he knows the concepts and what Afrezza can do.
|
|
|
Post by kc on May 17, 2018 9:36:03 GMT -5
Barnstormer...... Great write up just like Central Coast. I feel like a weight has been lifted off the back of MannKind. Mike and the team have a clear direction and the future has removed some of the storm clouds that could have wiped out MannKind. David Kindall is the real deal and will make it happen with his knowledge, contacts and the found research that MannKind already had.
|
|